What is known and objective: Febuxostat and allopurinol are xanthine oxidase inhibitors for urate-lowering therapy. The efficacy and safety of febuxostat and allopurinol have been mostly reported in hyperuricemia patients with normal renal function.
| WHAT IS NE W AND OBJEC TIVE
Hyperuricemia is a metabolic disorder that causes the level of serum uric acid (UA) to exceed the upper limit of the normal reference level.
Hyperuricemia is one of the common complications in renal transplant recipients, with an incidence rate from 25.1% at 3 months to 44.2% at 5 years after transplantation. 1 Risk factors for hyperuricemia include reduced renal allograft function and drugs (particularly calcineurin inhibitors and diuretics). [2] [3] [4] Studies have suggested a positive association between hyperuricemia and progression of disease in individuals with renal insufficiency, including chronic kidney disease (CKD) and unrecovered allograft kidney. [5] [6] [7] [8] [9] [10] Elevated serum UA is associated with abnormal endothelial function, mitochondria dysfunction and glomerular arteriolopathy and also could result in the formation of urate crystals in the nephron collecting ducts with tubular obstruction and then cause the damage of kidney structure progressively.
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Available UA-lowering agents include the xanthine oxidase inhibitors such as febuxostat, allopurinol and benzbromarone.
Benzbromarone increases the urinary excretion of uric acid, but the use of benzbromarone is limited due to reduced effects in patients with renal insufficiency and the risk of severe hepatotoxicity. 12 Febuxostat and allopurinol have both been shown to be efficacious in hyperuricemia and gout and are well tolerated, thus recommended for UA-lowering therapy, especially in patients with renal insufficiency. 13 While a more potent UA-lowering effect has been shown with febuxostat, there was no evidence that febuxostat is superior to allopurinol for clinically relevant outcomes and, given its higher cost, febuxostat should not be routinely used for chronic gout. 14 For patients with CKD, many studies have been reported the beneficial effects of febuxostat and allopurinol on renal function. A randomized controlled trial demonstrated that allopurinol reduced the rate of decline in GFR in patients with CKD with eGFR <60 mL/ min/1.73 m 2 . 15 Febuxostat showed a renoprotective effect and retarded the progression of kidney disease in patients compared with allopurinol. [16] [17] [18] [19] However, the impact of these two drugs on allograft renal function is conflicting. A retrospective analysis 20 of 54 renal transplant recipients using allopurinol demonstrated that allopurinol use was associated with preservation of eGFR in renal transplant recipients. Other studies found no apparent effect on eGFR for febuxostat 21 and did not find a difference in change of eGFR from baseline between febuxostat and allopurinol in stable renal transplant recipients. 22 Moreover, renal function can change over time in post-operative renal transplant recipients, 23 and it is plausible to hypothesize an effect of promoting renal function recovery of febuxostat or allopurinol based on the protective effect in renal insufficiency patients with CKD. It is therefore useful to study the time-varying effects of febuxostat and allopurinol on serum UA levels in post-renal transplant recipients with new onset of hyperuricemia. Data about the safety of febuxostat and allopurinol in post-renal transplant recipients also need to be replenished.
Thus, we performed a retrospective cohort study to compare the effects on reducing serum UA level, the influence on renal allograft function recovery and the safety between febuxostat and allopurinol in post-renal transplant recipients with hyperuricemia.
| ME THODS

| Study patients
We 
| Study design
This was a single-center, retrospective observational cohort study designed to compare the effects of febuxostat and allopurinol on lowering serum UA level, renal allograft function recovery and safety in early post-operative renal transplantation patients with hyperuricemia. The study was performed in accordance with
Febuxostat caused a marginally quicker serum UA-lowering effect than allopurinol, but there was no advantage for long-term use of febuxostat. The drugs had no significant differences in impacting renal allograft function recovery, and both were well 
| Data collection
| Statistical analysis
Statistical analyses and calculations were performed using SPSS or median ± interquartile range (IQR) if not normally distributed.
Qualitative variables are given as counts and ratios (%). Baseline variables were compared between febuxostat group and allopurinol group to detect any variability at baseline. Between-group comparison of numeric parametric data was done by unpaired t test or
Wilcoxon rank sum test. To determine differences between groups of categorical data (eg proportion of patients who achieve target serum uric acid), chi-square test or Fisher's exact test were used as applicable. P < 0.05 was considered statistically significant.
| RE SULTS
| Patient baseline characteristics
The flow chart in Figure 1 showed that 64 patients receiving febuxostat and 63 patients receiving allopurinol were screened for initial enrolment. With further exclusion, 48 patients in the febuxostat group and 33 patients in the allopurinol group were available for analysis. Baseline characteristics are presented in Serum uric acid is expressed in μmol/L, percentage change of serum uric acid level is expressed in %, and values are given as mean ± standard deviation. Percentage of patients who achieve target serum uric acid is expressed in %, and values are given as percentage (number of patients/total number). *P < 0.05 vs allopurinol in different time. Table 1 . There were no significant differences in the febuxostat and allopurinol groups with respect to baseline variables, apart from the level of high-density lipoprotein (HDL), which was higher in the febuxostat group at baseline. In the febuxostat group, three patients switched from 40 mg twice daily to 40 mg once daily according to the level of serum UA, and four patients increased the frequency to 40 mg once daily due to uncontrolled UA level at initial 40 mg once two days; the other 41 patients maintained 40 mg once daily throughout the study. In the allopurinol group, eight patients were given allopurinol sustained release capsules with 250 mg twice daily, five patients adjusted the sustained release capsules from 250 mg once 2 days to once daily based on the serum UA level, five patients using 50 mg allopurinol tablet changed the frequencies between once daily and twice daily, and the other 15 patients kept the tablet at 50 mg once daily throughout the study.
| Efficacy in lowering serum uric acid
The mean serum UA levels of febuxostat and allopurinol groups were 572.23 ± 117.80 μmol/L and 587.06 ± 106.11 μmol/L before the treatment (P > 0.05). As shown in Figure 2A and Table 2 , there was a decrease in UA levels in febuxostat and allopurinol groups after initiation of treatment, whereas the UA levels were significantly lower in febuxostat group than in allopurinol group on day 3, 7 and 15 and month 1 (P < 0.05). The most apparent difference was found on day 7, with UA levels 267.25 ± 93.66 μmol/L for febuxostat group and 334.18 ± 96.56 μmol/L for allopurinol group (P = 0.003). The significant differences between the two groups disappeared on months 3 and 6. Similar results were found in the serum UA decline proportion ( Figure 2B and Table 2 ). On day 7, the decline proportions were 52.92% ± 14.82% in the febuxostat group and 41.79% ± 15.28% in the allopurinol group (P = 0.002).
We investigated the effects of the two drugs on the percentage of patients achieving target serum UA level ( Figure 3 and Table 2) and observed that 62.50% and 30.30% of patients achieved target UA level in febuxostat and allopurinol group on day 3 respectively (P = 0.004), and the proportions were 93.75% and 75.76% on day 7 (P = 0.046). However, no significant differences were observed from day 15. Furthermore, Figure 4 showed that the median times to achieve target UA level was 3 days and 5 days in the febuxostat group and allopurinol group, respectively (P = 0.002).
Overall, the above data suggest that, compared to allopurinol, febuxostat may cause a slightly quicker serum UA-lowering effect at the beginning of treatment, but the advantage disappeared relatively quickly with the extension of treatment.
| Impacts on renal allograft function recovery
eGFR was adopted for evaluation of renal allograft function recovery. As shown in Figure 5A and However, no significant differences were found between the two groups in all of the monitoring time. Likewise, similar results were also found in the increasing rate of eGFR ( Figure 5B and Table 3 ).
| Safety
Common adverse drug reactions related to febuxostat and allopurinol include abnormalities of hematologic and hepatic functions.
Thus, laboratory data including WBC, PLT, Hb, ALT and AST were analyzed throughout the study, and no abnormities related to the F I G U R E 3 Percentage of patients who achieved target serum uric acid levels in febuxostat group and allopurinol group in different time. *P < 0.05
Time to reach target serum uric acid levels in febuxostat group and allopurinol group of early post-renal transplant recipients with new onset of hyperuricemia. *P <0.05. Spots stand for the time to reach target serum uric acid level for every patient. Straight horizontal lines stand for median and interquartile range two drugs were observed (Table 4) . Meanwhile, none of the patients in both groups experienced other adverse reactions related to febuxostat or allopurinol. During the study period, there happened one patient in the febuxostat group with ALT and AST levels rising from 11 U/L to 12 U/L in the beginning to 172 U/L and 95 U/L at month 1, which might be explained by the use of tacrolimus, because ALT and AST recovered to normal levels after switching tacrolimus to cyclosporine A. Besides, in the febuxostat group, one patient had leucopenia and another one had hyperkalemia. In the allopurinol group, one patient had hyperkalemia and another one had mild diarrhea. However, all of the above adverse reactions
were not considered to be related to febuxostat or allopurinol, since these reactions improved after discontinuation of other suspected drugs (such as mycophenolate mofetil induced diarrhoea and tacrolimus induced hyperkalemia) while continuing use of febuxostat or allopurinol.
| D ISCUSS I ON
In our present study, febuxostat was demonstrated to cause a slightly quicker serum UA lowering effect than allopurinol at the beginning of treatment, while the advantage disappeared with the extension of treatment. No significant differences were found between the two drugs in promoting the renal allograft function recovery. The therapy for hyperuricemia with febuxostat and allopurinol in postrenal transplant recipients were both well tolerated, and no severe adverse effects were observed.
Serum UA levels and decline proportions between febuxostat and allopurinol groups showed significant variances on days 3, 7
and 15 and month 1, but disappeared on months 3 and 6 in our study. A similar result was observed in another retrospective study 25 ; stable renal transplant recipients with hyperuricemia prescribed febuxostat, allopurinol and benzbromarone had no significant difference in serum UA levels on the months 1, 3, 6
and 12 (P > 0.05). This phenomenon may owe to the reason that both drugs had to be adjusted with lower dosage or reduced Although hyperuricemia has been known to negatively be correlated with eGFR and associated with the worsening of renal allograft function, 10 whether UA-lowering therapy using febuxostat or allopurinol plays a role in promoting renal allograft function recovery is still unclear. In our study, gradual recoveries of renal allograft function in both febuxostat and allopurinol group were demonstrated by increasing eGFR, and we found no significant variances between the two drugs in impacting eGFR increase. Febuxostat and allopurinol show a renoprotective effect and prevent the progression of renal disease in CKD patients. 15, 27 Febuxostat and allopurinol may have a promotion effect on renal allograft function recovery in early post-renal transplant recipients, but this needs further research.
No severe adverse effect was found in our study, which was confirmed by previous studies related to the safety of febuxostat or allopurinol in renal transplantation recipients. However, the safety of these two drugs in renal transplantation recipients still need to be verified by enlarging the number of patients and extending the follow-up period.
| WHAT IS NE W AND CON CLUS I ON
As we know, few studies have been reported on the effects of febuxostat and allopurinol in renal transplant recipients with hyperuricemia. A retrospective case-control study performed in renal transplant recipients suggested that allopurinol reduced serum UA levels and is associated with preservation of eGFR. 20 Besides, UA-lowering effects of febuxostat in renal transplant patients were also investigated. 21, 24 As compared to the reported studies, we compared the efficacy and safety of febuxostat and allopurinol.
In conclusion, febuxostat caused a slightly quicker serum UAlowering effect than allopurinol at the beginning of the treatment in early post-renal transplant recipients. There was no significant difference between the two drugs in impacting the renal allograft function recovery. Both drugs were well tolerated, but long-term safety needs to be further assessed. TA B L E 4 Safety of febuxostat and allopurinol in patients who used febuxostat or allopurinol to lower serum uric acid after having renal transplantation 
